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Abstract: Illness and treatment perceptions are vital for people self-managing co-morbid 
conditions with associated cardiovascular disease, such as type 2 diabetes (T2D). However, 
perceptions of a co-morbid condition and the use of multiple medicines have yet to be researched. 
This study investigated the illness and treatment perceptions of people with co-morbid T2D. The 
Brief Illness Perception Questionnaire (repeated for T2D, hypertension, and hyperlipidemia) 
and the Beliefs about Medicines Questionnaire Specific Concerns Scales (repeated for Oral 
hypoglycemic agents, anti-hypertensive medicines, and statins) were sent to 480 people manag-
ing co-morbid T2D. Data on the number of medicines prescribed were collected from medical 
records. Significantly different perceptions were found across the illnesses. The strongest effect 
was for personal control; the greatest control reported for T2D. Illness perceptions of T2D dif-
fered significantly from perceptions about hyperlipidemia. Furthermore, illness perceptions of 
T2D also differed from perceptions of hypertension with the exception of perceptions of illness 
severity. Hypertension and hyperlipidemia shared similar perceptions about comprehensibility, 
concerns, personal control, and timeline. Significant differences were found for beliefs about 
treatment necessity, but no difference was found for treatment concerns. When the number of 
medicines was taken as a between-subjects factor, only intentional non-adherence, treatment 
necessity beliefs, and perceptions of illness timeline were accounted for. Co-morbid illness 
and treatment perceptions are complex, often vary between illnesses, and can be influenced by 
the number of medicines prescribed. Further research should investigate relationships between 
co-morbid illness and treatment perception structures and self-management practices.
Keywords: co-morbidity, polypharmacy, illness perceptions, treatment perceptions, increasing 
numbers of medicines
Introduction
The Quality and Outcomes Framework for England tables 2008 to 2009 reported that 
the overall prevalence of diagnosed cases of diabetes was 5.1% (2,213,138 people).1 
Seventy percent of people with type 2 diabetes (T2D) also have premature cardio-
vascular disease (CVD).2 The associated risk of CVD-linked mortality is higher for 
people with T2D.3–5 Co-morbid T2D, hypertension, and hyperlipidemia represent parts 
of the same overall pathophysiologic risk profile and would be treated using the same 
disease management plan.6
Optimal self-management is an integral part of medical management for co-morbid 
T2D and is needed to avoid long term microvascular and macrovascular complications.7 
However, evidence suggests that the presence of co-morbidities negatively affects the 
ability of people to manage their conditions.8 For example, their motivation to act on risk 
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factors (often requiring behavior change), ability to  identifiy 
symptoms early, recognition of any deterioration of each 
condition, and successful management of complicated medi-
cation regimens may all be constrained.9 Furthermore, when 
multiple medicines are prescribed to people with co-morbid 
conditions, adherence can be adversely affected.10
Large, randomized controlled trials such as the United 
Kingdom Prospective Diabetes Study and the Collaborative 
Atorvastatin Diabetes Study advocate intensive pharmaco-
logical management of T2D.11,12 Most people with T2D are 
prescribed multiple medicines to improve metabolic con-
trol, lower serum glucose, cholesterol, and blood pressure. 
 However, many studies have found that adherence is affected 
by the frequency of doses and the number of medicines 
 prescribed.13 For example, Donnan et al found that once daily 
doses of oral hypoglycemic agents (OHAs) were associated 
with better adherence compared with multiple daily doses.14 
Stack et al found that people managing co-morbid T2D often 
prioritized some medicines over others, with medicines 
for hyperlipidemia management being perceived as less 
 important.15 Other studies found that when people are pre-
scribed large numbers of medicines, adherence to medicines 
for hyperlipidemia management decreased. A review of anti-
hypertensive medicines found that the adherence rate for a 
single daily dose was significantly higher than adherence to 
multiple daily doses.16 The way that multiple medicines are 
used may be driven by how patients understand and perceive 
their medicines, treatment, and co-morbid illness(es).
The self-regulation model provides a theoretical frame-
work to explain how illness perceptions inform coping 
strategies including self-management behaviors.17,18 The 
self-regulation model describes the perceptions common to 
people managing an illness and how those with an illness 
such as T2D make sense of, cope with, adjust to, and man-
age their condition. Illness and treatment perceptions are 
linked to self-management behaviors such as adherence to 
medicines,19,20 lifestyle modification, and self-monitoring.21 
The self-regulation model includes emotional (fear, worry, 
and depression) and cognitive (timeline, severity, identity, 
cause, and cure/control) representation of illness.  Cognitive 
representations include: identity, that is, beliefs about the 
labels attached to an illness and the symptoms associated 
with that illness; beliefs about the cause, which can include 
lifestyle, environment, or genetic factors; timeline beliefs, 
which relate to the perceived duration of the illness and 
whether it is acute or time limited, chronic or cyclical; 
beliefs about consequences, which reflect a range of the 
potential costs of an illness; physical, psychological, social, 
or financial beliefs and, finally, cure or control beliefs related 
to perceived curability, perceived treatment control, and 
perceived individual control.
The self-regulation model has been extended to explore 
beliefs about medicines. Horne suggests that people hold 
general beliefs about medicines which refer to medicines as 
a category of treatment.22 General beliefs include perceptions 
about the general harm that medicines cause and percep-
tions about overuse. Specific beliefs about treatment cover 
necessity beliefs and concerns about medicines. Treatment 
necessity beliefs are perceptions about personal need for 
medication for both current and future health. Examples of 
treatment necessity beliefs include beliefs about the effec-
tiveness of medicines or whether missing medications would 
have a negative impact on health. Concerns about medicines 
arise from beliefs about the potential negative effects of a 
medication. Little is known about the illness representa-
tions held by people living with co-existing or co-morbid 
 conditions. Yet chronic medical conditions most often occur, 
not as a single impairment or risk factor, but as multiple or 
co-morbid conditions for which multiple medicines may 
have been prescribed.23
There is no research on the way people with T2D perceive 
the presence of macrovascular complication as co-morbid 
conditions (particularly, hypertension and hyperlipidemia). 
The question of whether illness models of T2D differ (for 
example, more negative) from those for hypertension and 
hyperlipidemia needs to be addressed.  Characterizing 
the personal models of patients is important, in order to 
develop care plans and facilitate self- management, because 
 accurate understanding is pivotal to good care. Beliefs 
about co-morbid conditions may consist of separate per-
ceptions of each individual illness (an  additive model) 
or a more  coherent understanding of how they  interact 
(a  multiplicative model).
This research aimed to characterize the illness percep-
tions of people managing the co-morbid conditions of T2D, 
hypertension, and hyperlipidemia.
Method
Sample
Eight hundred and seventy-eight people with T2D and CVD 
were identified from a secondary care diabetes database in 
the United Kingdom. This register incorporated prescrib-
ing information from secondary and primary care, which 
enhanced the reliability of the data used in this research. 
Patients aged 18 years or more were included if they were 
prescribed 1 or more oral hypoglycemic agents for the 
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 treatment of T2D, 1 or more anti-hypertensive drugs, and a 
statin for the treatment of hyperlipidemia. People with a care 
or nursing home address were excluded as they were assumed 
to have less personal control over taking their medicines 
than community dwelling populations. People who had not 
attended the diabetes clinic at the hospital where the study 
was undertaken within 12 months of the study starting were 
not approached. This technique improved the response rate 
and ensured that people were not sent mail from healthcare 
services with which they had little or no contact.
Materials
The Brief Illness Perceptions Questionnaire, IPQ(b), includes 
1 item to represent each of the 7 main components of the 
IPQ-R: illness consequences; timeline; personal control; 
treatment control; identity; emotional concern; emotion 
and illness comprehensibility.24 Each item is measured on 
a 10-point Likert scale (from 1 to 10). The final, eighth, 
domain of the IPQ(b) asks respondents to state 3 causes of 
their illness. The IPQ(b) was repeated for T2D, hypertension, 
and hyperlipidemia separately to determine whether patient 
perceptions of each of these conditions differed.
The Beliefs about Medicines Specific Concerns Scales 
Questionnaire (BMQ) subscale measures treatment neces-
sity beliefs and concerns about specific medication.25 Each 
item used a 5-point Likert scale; scores range between 1 
and 5. The BMQ’s Specific Concerns subscale assesses the 
perceived treatment necessity and perceived concerns about 
medicines. The BMQ scales for treatment necessity beliefs 
and treatment control were used to access perceived treat-
ment necessity and concern about OHAs, anti-hypertensive 
medicines, and statins (each of the Specific Belief scales was 
presented 3 times).
number of medicines prescribed
The number of medicines prescribed was extracted from a 
secondary care hospital’s diabetes database. The number of 
medicines prescribed for T2D, hypertension, and hyperlipi-
demia were counted, added together, and used to construct a 
categorical between-subjects variable. To create a categorical 
variable, the number of medicines prescribed was divided 
into 3 groups. The groups were created to ensure an equal 
number of respondents for each category. Two hundred and 
thirty-two people were prescribed 3 medicines. This group 
was prescribed 1 medicine from each category: 1 OHA, 1 
anti-hypertensive, and 1 statin. Those prescribed 3 medicines 
had the lowest number of medicines and were the only group 
to consistently have the same medicines. One hundred and 
two people were prescribed between 4 and 5 medicines; 146 
people were prescribed 5 medicines or more; the maximum 
number of medicines prescribed in the group was 8.
Participants were sent the entire questionnaire battery, 
and were asked to return it when complete. The questionnaire 
battery presented the BMQ first and then IPQ(b) for each 
condition. Half of the questionnaire batteries sent presented 
the T2D scales first, followed by the hypertension, and 
hyperlipidemia scales. The other half of the questionnaire 
batteries presented the hypertension, hyperlipidemia, and 
then the T2D scales.
Procedure
Research ethics approval was obtained. The collaborating 
diabetologist with consent to access patient medical records 
used the eligibility criteria to identify eligible adults from 
the diabetes register based on the medicines prescribed. 
Questionnaires, an invitation letter, and a free post return 
envelope were sent to eligible participants. Two reminders 
were sent to increase the response rate 2 and then 4 weeks 
after the initial mailing.
Analysis
A repeated-measures ANOVA was used to explore treat-
ment variance in specific treatment beliefs across OHAs, 
anti-hypertensive medicines, and statins. A repeated measure 
ANOVA was used to explore variation in illness perceptions 
across T2D, hypertension, and hyperlipidemia. The number 
of medicines prescribed was added as a between-subjects 
factor to understand the effect of the number of medicines 
on treatment perceptions and illness perceptions.
Results
response rate
Of the 878 questionnaires sent, 23 were returned as either 
‘not known at this address’, or ‘addressee has gone away’, 42 
people returned a blank questionnaire or declined participa-
tion directly, so that the ‘active’ sample included 855 people. 
Of those, 480 (56%) questionnaires were finally returned.
Sample characteristics
Participants’ mean age was 66.3 years (range: 28–94 years), 
with 64.6% male (data were missing in 3 cases), 91.7% 
white, 1.8% Asian, and 0.4% from other backgrounds. Data 
on ethnicity were missing for 25 cases. Table 1 shows the 
range of medicines prescribed to participants. Of participants, 
21.5% reported an annual household income of less than 
£19,999; 7.9% reported an annual income above £20,000; 
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27.7% reported that they were retried, and 42.9% choose not 
to disclose their annual household income.
Within-subjects effects
Within-subjects ANOVAs were used to compare the mean 
scores given on 8 IPQ(b) domains/items in relation to T2D, 
hypertension, and hyperlipidemia, and the BMQ subscales 
in relation to OHAs, anti-hypertensive medicines, and 
statins. Table 2 shows the Wilks lambda statistic for each 
within-subjects ANOVA. Differences between perceptions 
held about T2D, hypertension, and hyperlipidemia were 
significant and partial eta squared was used to interpret the 
magnitude of the difference. The largest effect was reported 
for personal control indicating a large difference in perceived 
personal control between the illnesses.
illness severity
Participants perceived the severity for T2D to be greater 
than hyperlipidemia (mean difference = 1.285, P , 0.001, 
confidence interval [CI] [95%] 0.624–1.947) but not hyper-
tension (mean difference = 0.634, P = 0.279, CI [95%] −0.037 
to 1.305). Hypertension was perceived as more severe 
than hyperlipidemia (mean difference = 0.652, P , 0.001, 
CI [95%] 0.384–0.919).
illness timeline
T2D was thought to be longer lasting than hypertension 
(mean difference = 1.201, P , 0.001, CI [95%] 0.921–1.481) 
and hyperlipidemia (mean difference = 1.434, P , 0.001, 
CI [95%] 1.139–1.728). Timeline perceptions of hyperten-
sion and hyperlipidemia were also significantly different 
(mean difference = 0.233, P , 0.001, CI [95%] −0.034 to 
0.5); timeline perceptions of hypertension were thought to 
be longer.
Personal control
Participants perceived greater personal control over T2D than 
either hypertension (mean difference = 0.501, P , 0.001, CI 
[95%] 0.203–0.8) or hyperlipidemia (mean difference = 0.46, 
P , 0.001 CI [95%] 0.157–0.763). Personal control per-
ceptions for hypertension and hyperlipidemia were not 
significantly different (mean difference = 0.129, P = 1.000, 
CI [95%] −0.351 to 0.269).
Treatment control
Participants believed their treatment was more likely to 
control T2D than the subsequent treatment for either hyper-
tension (mean difference = 0.475, P , 0.001 CI [95%] 
0.259–0.69) or hyperlipidemia (mean difference = 0.754, 
P , 0.001, CI [95%] 0.522–0.986). The difference between 
perceptions of treatment control for hypertension and hyper-
lipidemia was also significant (mean difference = 0.279, 
P , 0.05, CI [95%] 0.026–0.532); participants held 
significantly stronger treatment control perceptions for 
hypertension.
illness identity
More symptoms were reported for T2D than either hyper-
tension (mean difference = 0.68, P , 0.001, CI [95%] 
0.358–1.001) or hyperlipidemia (mean difference = 1.245, 
P , 0.001, CI [95%] 0.926–0.1.565). Similarly, signifi-
cantly more symptoms were perceived for hypertension 
Table 1 numbers of participants prescribed each medication
Category of 
medication 
Name of medication  
sub-category
Number (%) 
prescribed 
OhAs Metformin 388 (80.33%)
glitazones 74 (15.42%)
Sulfonylureas 0 (0%)
Anti- 
hypertensives
Angiotensin i converting enzyme 
inhibitors
324 (67.5%)
calcium channel blockers 211 (43.96%)
Angiotensin ii receptor antagonists 128 (26.67%)
Diuretics 126 (26.25%)
Alpha-blocker 49 (10.21%)
Beta-blocker 0 (0%)
hMg coA reductase inhibitor (statins) 480 (100%)
Table 2 The within-subjects AnOVA statistics for iPQ(b) items
Wilks  
lambda
F df Sig. Partial eta 
squared
Severity 0.891 24.161 2,394 0.000 0.109
Timeline 0.706 78.201 2,376 0.000 0.294
Personal control 0.950 10.095 2,387 0.000 0.950
Treatment control 0.863 31.091 2,393 0.000 0.137
identity/symptoms 0.812 44.715 2,385 0.000 0.188
concerns 0.948 10.938 2,399 0.000 0.052
comprehensibility 0.882 25.795 2,387 0.000 0.118
emotion 0.804 47.217 2,388 0.000 0.196
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than  hyperlipidemia (mean difference = 0.566, P , 0.001, 
CI [95%]) 0.299–0.833).
illness concerns
More concerns were reported for T2D than for either 
hypertension (mean difference = 0.426, P , 0.05, CI [95%] 
0.075–0.778) or hyperlipidemia (mean difference = 0.686, 
P , 0.001, CI [95%] 0.332–1.04). No significant difference 
was found between the number of concerns for hypertension 
and hyperlipidemia (mean difference = 0.259, P = 0.195, CI 
[95%] −0.078 to 0.596).
illness comprehensibility
Greater understanding was reported for T2D than either 
hypertension (mean difference = 0.799, P , 0.001, CI [95%] 
0.475–1.124) or hyperlipidemia (mean difference = 0.943, 
P , 0.001, CI [95%] 0.613–1.274) but not between hyperten-
sion and hyperlipidemia (mean difference = 0.144, P = 0.683, 
CI [95%] −0.143 to 0.431).
illness emotion
The level of emotional distress associated with T2D 
was significantly higher than either hypertension (mean 
 difference = 0.438, P , 0.001, CI [95%] 0.147–0.73) 
or hyperlipidemia (mean difference = 1.192, P , 0.001, 
CI [95%] 0.884–1.501). Also, emotional distress associ-
ated with hypertension was greater than that associated 
with hyperlipidemia (mean difference = 0.754, P , 0.001, 
CI [95%] 0.496–1.012).
Treatment necessity
A repeated-measures ANOVA found a significant differ-
ence across medicines for treatment necessity beliefs (Wilks 
lambda = 0.804, F = 47.217, df = 2,388, P , 0.000, partial eta 
squared = 0.334). A post hoc analysis revealed that OHAs were 
associated with greater treatment necessity beliefs compared 
with anti-hypertensives (mean difference = 1.153, P , 0.000, 
CI [95%] 0.713–1.593) and statins (mean difference = 2.694, 
P , 0.000, CI [95%] 2.219–3.169). Anti- hypertensives had 
significantly higher treatment necessity beliefs compared with 
treatment necessity beliefs for statins (mean  difference = 1.542, 
P , 0.000, CI [95%] 1.079–2.004).
Treatment concerns
No significant difference was found for treatment concerns 
across medicines (Wilks lambda = 1, f = 0.068, df = 2,372, 
P = 0.935). Therefore, concerns about medicines did not vary 
between OHAs, anti-hypertensives, and statins.
Influence of the number of medicines 
prescribed on perceptions
The between-subjects effect for treatment necessity beliefs 
was not significant (f = 2.502, df = 2,370, P = 0.083). 
Therefore, treatment necessity beliefs did not increase as 
the number of medicines prescribed increased. The interac-
tion between treatment necessity beliefs and the number of 
medicines prescribed was significant (f = 2.559, df = 4,370, 
P , 0.05, partial eta squared = 0.014). The interaction was 
interpreted using a line graph. Figure 1 shows that treatment 
necessity beliefs for OHAs, anti-hypertensives, and statins 
have a different relationship with the number of medicines. 
Treatment necessity beliefs for anti-hypertensives differ for 
low, medium, and high numbers of medicines, whereas treat-
ment necessity beliefs for statins and OHAs do not appear to 
be affected by the number of medicines prescribed.
The between-subjects effect for treatment concerns was 
not significant (f = 0.220, df = 2,370, P = 0.802): therefore, 
the number of medicines prescribed did not influence the 
level of concern reported. Treatment concerns did not differ 
across OHA, anti-hypertensives, and statins, and the interac-
tion between treatment concerns and the number of medi-
cines prescribed was not significant (f = 1.696, df = 4,370, 
P = 0.150).
The between-subjects effect for illness severity was 
significant (f = 5.003, df = 2,314, P , 0.01, partial eta 
squared = 0.031). Therefore, scores on the IPQ(b) illness 
severity item increased as the number of medicines prescribed 
increased. The interaction was not significant: therefore, the 
number of medicines prescribed did not affect the illness sever-
ity scores given for individual illnesses (f = 0.974 df = 2,371, 
P = 0.390). There was a consistent relationship between the 
number of medicines and illness severity across illnesses. 
15
16
17
18
19
20
OHAs Anti-
hypert- 
ensives
Statins OHAs Anti-
hypert-
ensives
Statins 
Treatment necessity Treatment concerns 
4–5 medicines 
3 medicines 
6+ medicines
Medication category Medication category 
21
Figure 1 Treatment necessity beliefs and treatment concerns across medicines for 
low, medium and high numbers of medicines.
Abbreviation: OhAs, oral hypoglycemic agents.
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The between-subjects effect for illness timeline was 
not significant: therefore, IPQ(b) illness timeline scores 
did not significantly increase as the number of medicines 
prescribed increased (f = 2.456, df = 2,375, P = 0.087). 
The interaction between timeline scores across illnesses 
and the number of medicines prescribed was significant. 
Thus increases in the number of medicines prescribed 
affect timeline scores for the illnesses investigated in dif-
ferent ways (f = 4.132, df = 2,371, P , 0.01, partial eta 
squared = 0.026).  Hyperlipidemia was associated with 
greater timeline perceptions (perceived to last for longer) 
for people prescribed 6 or more medicines.
The between-subjects effect for personal control was not 
significant: perceptions of personal control did not differ 
significantly as more medicines were prescribed (f = 0.171, 
df = 2,314, P = 0.843). The interaction between the number 
of medicines prescribed and personal control beliefs across 
illnesses was not significant (f = 1.233, df = 2,371, P = 0.296). 
Therefore, personal control did not significantly increase as 
more medicines were prescribed and this relationship was 
consistent across illnesses.
The between-subjects effect for treatment control was 
not significant: treatment control did not differ as more 
medicines were prescribed (f = 0.716, df = 2,391, P = 0.489). 
The interaction was not significant: therefore, the number of 
medicines did not affect perceptions of treatment control for 
individual illnesses (f = 1.519, df = 2,371, P = 0.198).
The between-subjects effect for identity was significant 
(f = 3.610, df = 2,314, P , 0.05, partial eta squared = 0.022): 
therefore, identity perceptions (ie, the level of symptoms 
reported) were affected by the number of medicines pre-
scribed. For example, more symptoms were reported for 
higher numbers of medicines. The interaction between 
identity beliefs and the number of medicines prescribed 
was also significant (f = 2.522, df = 2,371, P , 0.05, partial 
eta squared = 0.043). Therefore, the number of medicines 
prescribed appears to affect identity beliefs about different 
illnesses in different ways. Increasing identity beliefs for 
T2D and hypertension are related to increasing numbers of 
medicines. Identity beliefs for hyperlipidemia do not increase 
as more medicines are prescribed.
The between-subjects effect for illness concerns was not 
significant: therefore, illness concerns did not significantly 
differ (or increase) as more medicines were prescribed 
(f = 0.246, df = 2,314, P = 0.782). The number of medicines 
prescribed did not influence illness concerns about individual 
illnesses (f = 2.109, df = 2,371, P = 0.079). Therefore, the 
interaction was not significant.
The between-subjects analysis did not find a  significant 
effect between the number of medicines prescribed and illness 
emotion (f = 0.915, df = 2,314, P = 0.173). The interaction was 
not significant: therefore, the number of medicines prescribed 
did not affect emotions for individual illnesses (f = 1.539, 
df = 2,371, P = 0.193). The between-subjects analysis found 
that illness comprehensibility did not differ as more medi-
cines were prescribed (f = 0.711, df = 2,314, P = 0.711). The 
interaction was not significant and the number of medicines 
prescribed did not affect illness comprehensibility levels for 
different illnesses (f = 1.858, df = 2,371, P = 0.118).
Conclusion
Differences in illness perceptions were found between T2D, 
hypertension, and hyperlipidemia. The strongest differences 
found were for personal control. Participants perceived 
that they had greater personal control over T2D than other 
 conditions. This suggests that they or healthcare profession-
als find T2D easier to control than other conditions. This 
finding may reflect the greater focus on diabetes structured 
education programmes for T2D self-management. Structured 
education sessions may empower patients to feel as though 
they have greater control over T2D, and that the treatment 
offered also provides better control, but to neglect CVD 
self-management. Other studies have reported that patients 
receiving structured education have a lack of awareness 
of macrovascular  disease.26 Furthermore, participants in 
this study also reported a greater understanding of T2D 
compared with other conditions, supporting the conclusion 
that a greater awareness of T2D exists, whereas CVD is 
generally less well understood and controlled. This may have 
implications for the way each condition is self-managed. 
For example, the consequences for self-management may 
include people focusing on reducing blood sugars rather than 
cholesterol reduction. How far patients’ beliefs about these 
aspects of their conditions affect their self-management is 
not clear from this study and warrants further work. Also, 
other ways of testing the level of factual understanding of 
co-morbid conditions was not examined within this study 
and variations in healthcare literacy among participants may 
limit these findings.
T2D and hyperlipidemia were found to be significantly 
different for all IPQ(b) items. Therefore, participants 
appeared to perceive T2D and hyperlipidemia as very dif-
ferent conditions. This finding questions whether patients 
perceive T2D and hyperlipidemia to be part of a co-morbid 
condition or as separate illnesses with individual etiolo-
gies and management strategies. If a separation had been 
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perceived between these two conditions, we could conclude 
that the level of healthcare literacy among people with co-
morbid conditions is low, especially knowledge of how ele-
ments of co-morbid T2D are related to each other. Similarly, 
perceptions of hypertension were also significantly different 
to all perceptions of T2D, with the exception of perceptions 
of illness severity; the consequences of T2D and hypertension 
were perceived to have a similar level of severity. Overall 
hyperlipidemia was perceived as a less severe condition with 
less severe consequences.
Perceptions of timeline, emotions, and identity showed 
a similar pattern of differences, with T2D being perceived 
to last longer, cause more emotional distress and a greater 
number of symptoms than hypertension and hyperlipidemia. 
Furthermore, hypertension was perceived to last longer, 
cause more emotional distress, and a greater number of 
symptoms than hyperlipidemia. T2D caused a greater amount 
of emotional distress than other conditions. Despite T2D, 
hypertension and hyperlipidemia being conditions for which 
symptoms are mild and in some cases asymptomatic, more 
symptoms were reported for T2D. The greater reporting 
of symptoms may be related to the higher level of distress 
associated with T2D. Other research has found a link between 
depression and the reporting of symptoms in T2D; further 
links were made to self-management with lower levels of 
adherence being reported,27 but more research is required to 
identify the relationship between emotion, symptoms, and 
self-management in co-morbid T2D.
Necessity beliefs did not change as more medicines 
were prescribed; however, the interaction between treatment 
necessity beliefs and the number of medicines prescribed was 
significant. Therefore, the number of medicines influences 
treatment necessity beliefs for a specific medication, possibly 
anti-hypertensives. The number of medicines prescribed did 
not influence treatment concerns and the interaction was not 
significant. Therefore, concerns about medicines for people 
with co-morbid T2D were stable and consistent across condi-
tions and between groups. This confirms the suggestion that 
concerns about treatment may not need to be differentiated 
(ie, each type of concern addressed) in an intervention. This 
finding suggests that a similar approach to addressing treat-
ment concerns can be taken for those with varying numbers 
of medicines.
Perceptions of treatment control did not significantly 
differ as more medicines were prescribed, and the inter-
action was not significant. Also, perceptions of illness 
severity, illness personal control, illness concerns, illness 
emotional concerns, and illness comprehensibility did not 
 significantly differ as more medicines were prescribed, 
and the  interaction was not significant. Intuitively more 
medicines should have been associated with more concerns 
and emotional distress. Yet our results indicate that more 
medicines are not related to concerns or emotional distress, 
which may be explained by the quality of care received 
from health providers by those prescribed large numbers of 
medicines. Other studies indicate that as multi-morbid and 
co-morbid conditions increase, the quality of care patients 
receive also increases.28–30 This suggests that people manag-
ing more severe conditions, and possibly more medicines, 
may experience less distress and cope better because of 
increases in the quality of care they receive. Further research 
is needed to explore the impact of quality of care on the 
concerns and emotional distress associated with greater 
numbers of medicines.
Perceptions of illness timeline were not affected by 
the number of medicines prescribed. The interaction was 
significant, however, and illness timeline perceptions for 
hypertension had a significantly different interaction with 
the number of medicines prescribed, compared with time-
line perceptions for T2D and hyperlipidemia. Therefore, 
perceptions of hypertension timeline and treatment neces-
sity beliefs for anti-hypertensives are both higher for those 
who are prescribed larger numbers of medicines. Identity 
perceptions (the level of symptoms reported) were affected 
by the number of medicines prescribed and the interaction 
was significant. Increased reporting of symptoms for T2D 
and hypertension were related to increasing numbers of 
medicines, while identity beliefs for hyperlipidemia did not 
increase as more medicines were prescribed.
This study was the first to examine differences and cohe-
siveness in co-morbid illness and treatment perceptions. We 
have shown that people with co-morbid T2D have multiple 
beliefs about their condition, which do not reflect 1 coherent 
illness. Our findings indicate that the IPQ(b), BMQ specific 
concerns, and BMQ necessity subscale when repeated for 
each medicine and illness can detect differences among 
beliefs between conditions. Also, this research is the first to 
examine the role that the number of medicines prescribed 
has on illness and treatment perceptions. We acknowledge 
that the IPQ(b) and BMQ were not designed to detect within-
group differences but their use in this way has extended 
their possible utility. This draws attention to the limitations 
of the self-regulation model when applied to the study of 
co-morbid conditions. Further research on the primacy of 
beliefs in co-morbid conditions, and measures that reflect 
this complexity, is required.
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Limitations
This study has limitations, although a good response rate for 
an unsolicited survey was achieved. There is still a risk that 
the survey may have over sampled people with particular 
self-management behaviors or perceptions who present for 
secondary care. Furthermore, this cross-sectional study gives 
us little information about how co-morbid illness perceptions 
develop over time. The level of factual understanding of 
co-morbid conditions was not examined within this study 
and variations in healthcare literacy among participants 
may limit these findings. Future research should address this 
issue as it may account for some of the variance in illness 
beliefs. Co-morbid T2D, hypertension, and hyperlipidemia 
are related conditions and the lifestyle changes that are 
required overlap. Future research should explore perceptions 
of other co-morbidities that require explicitly different sets 
of management activities, and investigate the differences in 
illness and treatment perceptions.
relevance to clinical practice
Individuals self-managing co-morbid T2D are likely to hold 
different perceptions of their illness; this variation has been 
linked to the number of medicines prescribed, and therefore, 
variations in self-management behaviors are also likely. For 
example, the approach taken to manage T2D and hyperlipi-
demia may differ because the beliefs held for both conditions 
are significantly different. Qualitative research has shown that 
patients often view T2D as severe and requiring pharmaco-
logical management, while hyperlipidemia is perceived to be 
less severe, with many believing that this condition should be 
managed through lifestyle modification and that cholesterol 
lowering medicines were unnecessary.15 Healthcare profes-
sionals must recognize that people self-managing co-morbid 
conditions and prescribed multiple medicines, are likely to 
hold different perceptions about their conditions which may 
be influenced by the number of medicines they are being 
prescribed, and may adopt different self-management strate-
gies in response to their beliefs.
Understanding patients’ personal models of co-morbid 
conditions is essential for understanding self-management 
behaviors in people with T2D. Interventions that reduce risk 
factors through lifestyle modification, could improve health 
outcomes for people with T2D, particularly if they target 
unhelpful or incorrect perceptions.31 The findings of this 
research indicate that exploring perceptions about co-morbid 
conditions and multiple medicines is not a straightforward 
task for healthcare professionals and more valid and reliable 
measures are required to address this complexity.
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